Literature DB >> 32247376

Mechanisms of alpha-synuclein toxicity: An update and outlook.

Inês Caldeira Brás1, Mary Xylaki1, Tiago Fleming Outeiro2.   

Abstract

Alpha-synuclein (aSyn) was identified as the main component of inclusions that define synucleinopathies more than 20 years ago. Since then, aSyn has been extensively studied in an attempt to unravel its roles in both physiology and pathology. Today, studying the mechanisms of aSyn toxicity remains in the limelight, leading to the identification of novel pathways involved in pathogenesis. In this chapter, we address the molecular mechanisms involved in synucleinopathies, from aSyn misfolding and aggregation to the various cellular effects and pathologies associated. In particular, we review our current understanding of the mechanisms involved in the spreading of aSyn between different cells, from the periphery to the brain, and back. Finally, we also review recent studies on the contribution of inflammation and the gut microbiota to pathology in synucleinopathies. Despite significant advances in our understanding of the molecular mechanisms involved, we still lack an integrated understanding of the pathways leading to neurodegeneration in PD and other synucleinopathies, compromising our ability to develop novel therapeutic strategies.
© 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; Dementia Lewy bodies; Inflammation; Microbiota; Multiple system atrophy; Parkinson's disease; Pure autonomic failure; Spreading; Synucleinopathies; Toxicity

Mesh:

Substances:

Year:  2019        PMID: 32247376     DOI: 10.1016/bs.pbr.2019.10.005

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  11 in total

1.  All-or-none amyloid disassembly via chaperone-triggered fibril unzipping favors clearance of α-synuclein toxic species.

Authors:  Aitor Franco; Pablo Gracia; Adai Colom; José D Camino; José Ángel Fernández-Higuero; Natalia Orozco; Alexander Dulebo; Leonor Saiz; Nunilo Cremades; Jose M G Vilar; Adelina Prado; Arturo Muga
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-07       Impact factor: 11.205

2.  α-Synuclein Impacts on Intrinsic Neuronal Network Activity Through Reduced Levels of Cyclic AMP and Diminished Numbers of Active Presynaptic Terminals.

Authors:  Kristian Leite; Pretty Garg; F Paul Spitzner; Sofia Guerin Darvas; Mathias Bähr; Viola Priesemann; Sebastian Kügler
Journal:  Front Mol Neurosci       Date:  2022-05-03       Impact factor: 6.261

3.  Lafora Disease and Alpha-Synucleinopathy in Two Adult Free-Ranging Moose (Alces alces) Presenting with Signs of Blindness and Circling.

Authors:  Madhu Ravi; Atilano Lacson; Margo Pybus; Mark C Ball
Journal:  Animals (Basel)       Date:  2022-06-25       Impact factor: 3.231

4.  MANF Inhibits α-Synuclein Accumulation through Activation of Autophagic Pathways.

Authors:  Jing-Xing Zhang; Wei-Fang Tong; Ming Jiang; Kai-Ge Zhou; Xue-Rui Xiang; Yi-Jing He; Zhuo-Yu Zhang; Qiang Guan; Ling-Jing Jin
Journal:  Oxid Med Cell Longev       Date:  2022-07-08       Impact factor: 7.310

Review 5.  Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson's disease.

Authors:  Alcmène Chalazonitis; Meenakshi Rao; David Sulzer
Journal:  NPJ Parkinsons Dis       Date:  2022-04-22

6.  Neural-Induced Human Adipose Tissue-Derived Stem Cells Conditioned Medium Ameliorates Rotenone-Induced Toxicity in SH-SY5Y Cells.

Authors:  Mahesh Ramalingam; Sujeong Jang; Han-Seong Jeong
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

7.  BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson's disease.

Authors:  Zagorka Vitic; Hazem Safory; Vukasin M Jovanovic; Yael Sarusi; Alexandra Stavsky; Joy Kahn; Alona Kuzmina; Lilah Toker; Daniel Gitler; Ran Taube; Roland H Friedel; Simone Engelender; Claude Brodski
Journal:  Brain       Date:  2021-03-03       Impact factor: 13.501

Review 8.  Unzipping the Secrets of Amyloid Disassembly by the Human Disaggregase.

Authors:  Aitor Franco; Lorea Velasco-Carneros; Naiara Alvarez; Natalia Orozco; Fernando Moro; Adelina Prado; Arturo Muga
Journal:  Cells       Date:  2021-10-14       Impact factor: 6.600

9.  The intricate debate on neurodegeneration and neuroinflammation in Parkinson's disease: which came first?

Authors:  Antonella Cardinale; Valeria Calabrese
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

Review 10.  Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.